FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
JUBILANT Share Price Target
Jubilant Life Sciences Ltd.
NSE: JUBILANT | BSE: 530019 | ISIN: INE700A01033 | Sector: Pharmaceuticals and health care
JUBILANT Rating
- ★★
- ★★
- ★★
- ★★
- ★★
4.5/5 (12 Ratings)
JUBILANT Share Price *
516 -8.05 (-1.54%)
* (quote may be delayed)
10 JUBILANT share price target reports by brokerages below. See what is analyst's view on JUBILANT share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
You can also find JUBILANT share price target tomorrow or next week from JUBILANT discussion forum.
JUBILANT Share Price Forecast - Consensus
| No. of reports in last year | 10 |
| No. of analysts | 6 |
| Average Consensus Forecast | 709.80 |
| Consensus Potential | 22.67% |
JUBILANT Share Price Target - Broker Reports - 2020
Nirmal Bang
1-Feb-20
Price @ Call: 558.61
Target: 792
BUY
Prabhudas Lilladher
31-Jan-20
Price @ Call: 597.07
Target: 488
REDUCE
JUBILANT guided for favourable outcome of legal issues in Ruby-fill, new capacity in CDMO and FDA resolution of regulatory issues which may help in back-ended revenue growth in FY22E. The company however maintained heavy capex in FY21E. In our SOTP valuation, we increased EV/EBITDA of pharma business to 5.5x (from 5x) of FY22E while same for LSI maintained at 3x for commoditized LSI business. This has derived new TP of Rs488 (from Rs433). We maintain Reduce.
JUBILANT Share Price Target - Broker Reports - 2019
Nirmal Bang
29-Oct-19
Price @ Call: 542.7
Target: 792
BUY
We have revised our financial estimates on JLS for FY20 and FY21 to account for the revised prices in the commodity chemicals business. We have also made minor changes in our costs related assumptions. We have rolled over the valuation to September FY22 with a target P/E multiple of 12x to arrive at a target price (TP) of Rs792 (from Rs834 earlier).
Prabhudas Lilladher
25-Oct-19
Price @ Call: 566.85
Target: 433
REDUCE
JUBILANT raised US$200m debt and prepaid US$135m FCCB from IFC Washington. Its net debt reduced by Rs1.49bn in Q2FY20. Management has proposed demerger of Pharma and LSI business to unlock value of both the businesses, though shareholding to reflect mirror image. It guided for nine months to complete the process with approval from NCLT. Management plans to remain in old tax regime with guidance of effective annual tax outflow of 25% while reported tax liability to be 29-30%. We maintain ‘Reduce’ recommendation and retain TP at Rs433.
HDFC Securities
29-Jul-19
Price @ Call: 445.85
Target: 845
BUY
Concerns overplayed We maintain BUY on JUBILANT following an 8/12% beat on our EBITDA/PAT estimates for 1QFY20. Our TP is revised at Rs 845 (12x Jun-21E EPS) with a 5/10% cut to our FY20/21E EPS due to higher interest cost and tax rate.
Nirmal Bang
29-Jul-19
Price @ Call: 445.85
Target: 785
BUY
We revise our financial estimates on JLS for FY20 and FY21 to account for the revised prices in commodity chemicals business, ongoing impact of remediation measures on supply of API / solid dosage business and lower our estimates for Ruby fill for FY21. lower our target P/E multiple to 12x from 13x and arrive at a target price (TP) of Rs785.
Dolat Capital
24-May-19
Price @ Call: 516.5
Target: 750
BUY
We expect the pharma business to be stable as RubyFill is gaining market share. However, considering Roorkee WL, pressure on LSI, and a higher tax rate, we have a negative view for FY20 than our earlier assumption. We expectthe improving situation for Vitamin B3 and CMO’s additional capacities(starting a second line in H2FY20, commissioning Lyo in FY20) to provide aid tothe company’s performance. Considering the recent correction in the market,we have a BUY rating, with a TP of Rs 750 (10x FY21E EPS).
Motilal Oswal
20-May-19
Price @ Call: 564.8
Target: 800
BUY
We reduce our EPS estimate by 5%/7% for FY20/21 to factor in remediation cost associated with compliance in the pharma segment, further penalties associated with non-supplies to customers, and reduced prices in LSI products. We also reduce EV/EBITDA multiple for pharma to 9x (prior: 10x) and for LSI to 5x (prior: 6x) to factor in (a) regulatory risk in the pharma segment, (b) gradual pick-up in radio-pharma, and (c) subdued outlook for the Life Science Chemical Segment. Accordingly, we roll our price target to INR800 on SOTP-based valuation. At CMP of INR595, JUBILANT trades at an attractive valuation of 6.3x FY20 EV/EBITDA and 5.7x FY21 EV/EBITDA. Maintain Buy.
ICICIdirect.com
20-May-19
Price @ Call: 596.05
Target: 710
BUY
We expect specialty pharma to maintain growth momentum thanks strong growth and prospects for CDMO business. However, Official action Indicated (OAI) status to Nanjangud API facility is a likely stumbling block in the near term. Similarly, on the generics front, we expect some slowdown and costs escalation on account of warning letter to Roorkee facility. On the LSI front, despite inventory adjustment, EBITDA margins were disappointing and things are unlikely to improve in the next few quarters. In this backdrop, the performance pharma will be the main lever in the near future. We cut our EPS estimates by ~20% in both FY20 and FY21 due to these factors. We arrive at our target price of ~| 710 based on 10x FY21E EPS of Rs 70.8.
Prabhudas Lilladher
11-Mar-19
Price @ Call: 768.5
Target: 703
REDUCE
We cut our earnings estimates by 2.2% and 3.9% in FY20E and FY21E respectively, following assumptions of lower sales growth in US formulation. We expect that negative impact of the event as well as raising new debt capital will result in compression of PE multiples. We reduce assigned EV/EBTIDA to 7.5x (from 8.5x) on FY21E in our SOTP valuations of the company. The current valuation reflects all possible positive developments in the near to medium term. With muted demand offtake in chemical biz (LSI), higher leverage and regulatory uncertainties, we downgrade our recommendation to ‘Reduce’ and lower TP to Rs703 (Rs822 earlier).
Dolat Capital
8-Feb-19
Price @ Call: 756.71
Target: 900
BUY
HDFC Securities
6-Feb-19
Price @ Call: 740
Target: 1070
BUY
ICICIdirect.com
5-Feb-19
Price @ Call: 733.1
Target: 905
BUY
Motilal Oswal
4-Feb-19
Price @ Call: 711.55
Target: 1050
BUY
Prabhudas Lilladher
1-Feb-19
Price @ Call: 714.77
Target: 822
ACCUMULATE
Indiabulls Ventures
22-Jan-19
Price @ Call: 701.5
Target: 814
BUY
JUBILANT Share Price Target - Broker Reports - 2018
HDFC Securities
24-Dec-18
Price @ Call: 712.89
Target: 980
BUY
Motilal Oswal
5-Dec-18
Price @ Call: 818.95
Target: 965
BUY
HDFC Securities
23-Oct-18
Price @ Call: 651.25
Target: 980
BUY
ICICIdirect.com
23-Oct-18
Price @ Call: 651.25
Target: 945
BUY
Dolat Capital
23-Oct-18
Price @ Call: 651.25
Target: 900
BUY
Prabhudas Lilladher
22-Oct-18
Price @ Call: 672.65
Target: 723
ACCUMULATE
HDFC Securities
30-Jul-18
Price @ Call: 768.6
Target: 990
BUY
ICICIdirect.com
30-Jul-18
Price @ Call: 768.6
Target: 930
BUY
Motilal Oswal
28-Jul-18
Price @ Call: 801.49
Target: 1020
BUY
Prabhudas Lilladher
28-Jul-18
Price @ Call: 801.49
Target: 880
ACCUMULATE
AnandRathi
18-Jun-18
Price @ Call: 765.8
Target: 1040
BUY
HDFC Securities
10-May-18
Price @ Call: 857.8
Target: 1060
BUY
ICICIdirect.com
10-May-18
Price @ Call: 846.75
Target: 1080
BUY
Motilal Oswal
10-May-18
Price @ Call: 846.75
Target: 1110
BUY
Prabhudas Lilladher
10-May-18
Price @ Call: 846.75
Target: 937
ACCUMULATE
ICICIdirect.com
18-Jan-18
Price @ Call: 921.25
Target: 1090
BUY
Motilal Oswal
18-Jan-18
Price @ Call: 921.25
Target: 1110
BUY
Motilal Oswal
8-Jan-18
Price @ Call: 777.6
Target: 957
BUY
JUBILANT Share Price Target - Broker Reports - 2017
Indiabulls Ventures
14-Dec-17
Price @ Call: 670.8
Target: 893
BUY
Motilal Oswal
31-Oct-17
Price @ Call: 639.6
Target: 861
BUY
ICICIdirect.com
19-Jul-17
Price @ Call: 718
Target: 845
BUY
Motilal Oswal
18-Jul-17
Price @ Call: 704
Target: 905
NEUTRAL
Edelweiss
4-Jul-17
Price @ Call: 692
Target: 905
BUY
ICICIdirect.com
8-Feb-17
Price @ Call: 704
Target: 810
BUY
JUBILANT Share Price Target - Broker Reports - 2016
ICICIdirect.com
27-May-16
Price @ Call: 343
Target: 405
BUY
Prabhudas Lilladher
28-Oct-16
Price @ Call: 649
Target: 740
ACCUMULATE
ICICIdirect.com
28-Oct-16
Price @ Call: 649
Target: 795
BUY
Systematix Shares & Stocks
5-Oct-16
Price @ Call: 642.5
Target: 750
ACCUMULATE
ICICIdirect.com
3-Oct-16
Price @ Call: 653
Target: 795
BUY
ICICIdirect.com
31-Aug-16
Price @ Call: 538.41
Target: 635
BUY
ICICIdirect.com
11-Aug-16
Price @ Call: 367
Target: 405
BUY
Prabhudas Lilladher
11-Aug-16
Price @ Call: 363.5
Target: 484
BUY
Prabhudas Lilladher
5-Jul-16
Price @ Call: 320.07
Target: 484
BUY
- keyboard_arrow_down
JUBILANT Peer Stocks - Share Price Targets
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.